Intervention Review

You have free access to this content

Interventions for smoking cessation and reduction in individuals with schizophrenia

  1. Daniel T Tsoi1,*,
  2. Mamta Porwal2,
  3. Angela C Webster3

Editorial Group: Cochrane Tobacco Addiction Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 10 JAN 2013

DOI: 10.1002/14651858.CD007253.pub3


How to Cite

Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD007253. DOI: 10.1002/14651858.CD007253.pub3.

Author Information

  1. 1

    Nottinghamshire Healthcare NHS Trust, Nottingham, UK

  2. 2

    Cancer Council NSW, Woolloomooloo, NSW, Australia

  3. 3

    The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

*Daniel T Tsoi, Nottinghamshire Healthcare NHS Trust, Institute of Mental Health, Jubilee Campus, University of Nottingham, Wollaton Road, Nottingham, NG8 1BB, UK. daniel.tsoi@nottshc.nhs.uk. t.tsoi@sheffield.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

[Figure 1]
Figure 1. Summary of the process of identifying randomised trials for inclusion
[Figure 2]
Figure 2. Bupropion versus placebo: Abstinence at 6-month follow-up (primary outcome)
[Figure 3]
Figure 3. Bupropion versus placebo: Mental state outcomes
[Figure 4]
Figure 4. Varenicline versus placebo: Abstinence at the end of treatment (secondary outcome)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Bupropion versus placebo, Outcome 1 Abstinence at 6-month follow-up (primary outcome).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Bupropion versus placebo, Outcome 2 Abstinence at end of treatment (secondary outcome).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Bupropion versus placebo, Outcome 3 Mental state outcomes - abstinence studies.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Bupropion versus placebo, Outcome 4 Reduction - Expired CO level at the end of treatment (secondary outcome) - abstinence studies.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Bupropion versus placebo, Outcome 5 Reduction - Expired CO level at 6-month follow-up (secondary outcome) - abstinence studies.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Bupropion versus placebo, Outcome 6 Reduction - Change in number of CPD from baseline at the end of treatment (secondary outcome) - abstinence studies.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Bupropion versus placebo, Outcome 7 Reduction - Change in number of CPD from baseline at 6-month follow-up (secondary outcome) - abstinence studies.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Bupropion versus placebo, Outcome 8 Reduction - Change in number of CPD from baseline at the end of treatment (secondary outcome) - reduction studies.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Varenicline versus placebo, Outcome 1 Abstinence at 6-month follow-up (primary outcome).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Varenicline versus placebo, Outcome 2 Abstinence at end of treatment (secondary outcome).